A Randomized, Adaptive, Investigator/ Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs RG7835 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Roche
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 27 Feb 2019 Planned End Date changed from 4 Dec 2018 to 17 Apr 2019.
- 27 Feb 2019 Planned primary completion date changed from 4 Dec 2018 to 17 Apr 2019.